Polymorphisms of interleukin-4, -10 and 12B genes and diabetic retinopathy

Central European Journal of Biology

Volumn 6, Issue 4, 2011, Pages 558-564

  Cilenšek, Ines ^a   Hercegovac, Amela ^b   Starčević, Jovana Nikolajević ^a   Vukojević, Katarina ^c   Babić, Mirna Saraga ^c   Živin, Aleksandra Milutinović ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY OF TUZLA   (Bosnia and Herzegovina)

^c UNIVERSITY OF SPLIT   (Croatia)

Author keywords

Gene polymorphism; Interleukin 10; Interleukin 12B; Interleukin 4; Proliferative diabetic retinopathy

Indexed keywords

EID: 79956327408     PISSN: 1895104X     EISSN: 16443632     Source Type: Journal    
DOI: 10.2478/s11535-011-0036-6     Document Type: Article

References (42)

1. Quresh M., Gillies M. C., Wong T. Y., Managment of Diabetic retinopathy, JAMA, 2007, 298, 902-916.
2. Fong D. S., Aiello L., Gardner T. W., King G. L., Blankenship G., Cavallerno J. D., et al., Diabetic retinopathy, Diabetes care, 1998, 21, 143-156.
3. Petrovic M. G., Osredkar J., Saraga-Babić M., Petrovic D., K469E polymorphism of the intracellular adhesion molecule 1 gene is associated with proliferative diabetic retinopathy in Caucasians with type 2 diabetes, Clin. Exp. Ophthalmol., 2008, 36, 468-472.
4. Petrovic M. G., Korosec P., Kosnik M., Osredkar J., Hawlina M., Peterlin B., et al., Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy, Mol. Vis., 2008, 14, 1382-1387.
5. Petrovic M. G., Krkovic M., Osredkar J., Hawlina M., Petrovic D., Polymorphisms in the promoter region of the basic fibroblast growth factor gene and proliferative diabetic retinopathy in Caucasians with type 2 diabetes, Clin. Exp. Ophthalmol., 2008, 36, 168-172.
6. Kariz S., Grabar D., Krkovic M., Osredkar J., Petrovic D., Polymorphisms in the promoter region of the basic fibroblast growth factor gene are not associated with myocardial infarction in a Slovene population with type 2 diabetes, J. Int. Med. Res., 2009, 37, 1596-1603.
7. Adamis A. P., Miller J. W., Bernal M. T., D'Amico D. J., Folkman J., Yeo T. K., Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy, Br. J. Ophtalmol., 2002, 86, 311-315.
8. Kern T. S., Contributions of inflammatory Processes to the development of the Early Stages of Diabetic Retinopathy, Exp. Diabetes Res., 2007, 95103, 1-14.
9. Petrovic M. G., Korosec P., Kosnik M., Hawlina M., Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy, Am. J. Ophthalmol., 2007, 143, 175-176.
10. Petrovic D., Vascular endothelial growth factor gene polymorphisms and myocardial infarction, Cardiology, 2009, 114, 8-10.
11. Petrovic D., Verhovec R., Globocnik Petrovic M., Osredkar J., Peterlin B., Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes, Cardiology, 2007, 107, 291-295.
12. Zorena K., Myśliwska J., Myśliwiec M., Balcerska A., Lipowski P., Raczyńska K., Interleukin-12 and tumour necrosis factor-alpha equilibrium is a prerequisite for clinical course free from late complications in children with type 1 diabetes mellitus, Scand. J. Immunol., 2008, 67, 204-208.
13. Hernandez C., Segura R. M., Fonollosa A., Carrasco E., Francisco G., Simo R., Interleukin -8 monocyte chemoattractant protein -1 and IL -10 in the vitreous fluid of patients with proliferative diabetic retinopathy, Diabetic Medicine, 2005, 22, 719-722.
14. Lin M. T., Storer B., Martin P. J., Tseng L. H., Gooley T., Chen P. J., et al., Relation of an interleukin - 10 promoter polymorphisms to graft - versus - host disease and survival afterhematopoietic - cell transplantation, N. Engl. J. Med., 2003, 349, 2201-2210.
15. Turner D. M., Williams D. M., Sankaran D., Lazarus M., Sinnott P. J., Hutchinson I. V., An investigation of polymorphism in the interleukin -10 gene promoter, Eur. J. Immunogenet., 1997, 24, 1-8.
16. Lee J. H., Lee W., Kwon O. H., Kim J. H., Kwon O. W., Kim K. H., et al., Cytokine profile of peripheral blood in type 2 diabetes mellitus patients with diabetic retinopathy, Ann. Clin. Lab. Sci., 2008, 38, 361-367.
17. Ozturk T. B., Bozkurt B., Kerimoglu H., Okka M., Kamis U., Gunduz K., Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness, Molecular Vision, 2009, 15, 1906-1914.
18. Paffen E., Medina P., de Visser M. C., van Wijngaarden A., Zorio E., Estellés A., et al., The -589C>T polymorphism in the interleukin-4 gene (IL-4) is associated with a reduced risk of myocardial infarction in young individuals, J. Thromb. Haemost., 2008, 6, 1633-1638.
19. Vairaktaris E., Yannopoulos A., Vassiliou S., Serefoglou Z., Vylliotis A., Nkenke E., et al., Strong association of interleukin -4 (-590C/T) with increased risk for oral squamos cell carcinoma in Europeans, Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 2007, 104, 6, 796-802.
20. Vairaktaris E., Yapijakis C., Serefoglou Z., Avgoustidis D., Critselis E., Spyridonidou S., et al., Gene expression polymorphisms of interleukins -1β, -4, -6, -8, -10, and tumor necrosis factors -α, -β: - regression analysis of their effect upon oral squamous cell carcinoma, J. Cancer Res. Clin. Oncol., 2008, 134, 821-823.
21. Volpert V. O., Fong T., Koch E. A., Peterson D. J., Waltenbaugh C., Tepper I. R., et al., Inhibition of Angiogenesis by Interleukin 4, J. Exp. Med., 1998, 188, 1039-1046.
22. Morahan G., McKinnon E., Berry J., Browning B., Julier C., Pociot F., et al., Evaluation of IL12B as a candidate type I diabetes susceptibility gene using data from the Type I Diabetes Genetics Consortium, Genes Immun., 2009, 10, S64-S68.
23. Huang D., Cancilla M. R., Morahan G., Complete primary structure, chromosomal localisation, and definition of polymorphisms of the gene encoding the human interleukin-12 p40 subunit, Genes Immun., 2000, 1, 515-520.
24. Mattner F., Fischer S., Guckes S., Jin S., Kaulen H., Schmitt E., et al., The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer, Eur. J. Immunol., 1993, 23, 2202-2208.
25. Hall M. A., McGlinn E., Coakley G., Fisher S. A., Boki K., Middleton D., et al., Genetic polymorphism of IL-12 p40 gene in immune-mediated disease, Genes Immun., 2000, 1, 219-224.
26. Morahan G., Huang D. X., Ymer S. I., Cancilla M. R., Stephen K., Dabadghao P., et al., Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele, Nat. Genet., 2001, 27, 218-221.
27. Perrey C., Pravica V., Sinnott P. J., Hutchinson I. V., Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report, Transpl. Immunol., 1998, 6, 193-197.
28. Bergholdt R., Ghandil P., Johannesen J., Kristiansen O. P., Kockum I., Luthman H., et al., Genetic and functional evaluation of an interleukin-12 polymorphism (IDDM18) in families with type 1 diabetes, J. Med. Genet., 2004, 41, e39.
29. Mtiraoui N., Ezzidi I., Kecem M., Mohamed M. B. H., Chaieb M., Jilani A. B. H., et al., Predictive value of interleukin 10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients, Diabetes Metab. Res. Rev., 2008, 25, 57-63.
30. Myśliwska J., Zorena K., Semetkowska-Jurkiewicz E., Rachoń D., Suchanek H., Myśliwski A., High levels of circulating interleukin-10 in diabetic nephropathy patients, Eur. Cytokine Netw., 2005, 16, 117-122.
31. Dace D. S., Khan A. A., Kelly J., Apte R. S., Interleukin-10 Promotes Pathological Angiogenesis by Regulating Macrophage Response to Hypoxia during Development, PLoS One., 2009, 4, e7121.
32. Lee I. Y., Kim J., Ko E. M., Jeoung E. J., Kwon Y. G., Choe J., Interleukin-4 inhibits the vascular endothelial growth factor- and basic fibroblast growth factor-induced angiogenesis in vitro, Mol. Cells., 2002, 14, 115-121.
33. Toi M., Harris A. L., Bicknell R., Interleukin-4 is a potent mitogen for capillary endothelium, Biochem. Biophys. Res. Commun., 1991, 174, 1287-1293.
34. Fukushi J., Morisaki T., Shono T., Nishie A., Torisu H., Ono M., et al., Novel biological functions of interleukin-4: formation of tube-like structures by vascular endothelial cells in vitro and angiogenesis in vivo, Biochem. Biophys. Res. Commun., 1998, 250, 444-448.
35. Boyle D. L., Nguyen K. H., Zhuang S., Shi Y., McCormack J. E., Chada S., et al., Intra-articular IL-4 gene therapy in arthritis: anti-inflammatory effect and enhanced th2activity, Gene Ther., 1999, 12, 1911-1918.
36. Hillman G. G., Younes E., Visscher D., Ali E., Lam J. S., Montecillo E., Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model, Cell Immunol., 1995, 160, 257-263.
37. Song Z., Casolaro V., Chen R., Georas S. N., Monos D., Ono S. J., Polymorphic nucletides within the human IL -4 promoter that mediate overexpression of the gene, J. Immunol., 1996, 156, 424-429.
38. Seegers D., Zwiers A., Strober W., Peña A. S., Bouma G., A TaqI polymorphism in the 3'UTR of the IL-12 p40 gene correlates with increased IL-12 secretion, Genes Immun., 2002, 3, 419-423.
39. Sgadari C., Angiolillo A. L., Tosato G., Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10, Blood, 1996, 1, 3877-3882.
40. Winkler G., Dworak O., Salamon F., Salamon D., Speer G., Cseh K., Increased interleukin-12 plasma concentrations in both, insulin-dependent and noninsulin-dependent diabetes mellitus, Diabetologia, 1998, 41, 488-494.
41. Poulaki V., Qin W., Joussen A. M., Hurlbut P., Wiegand S. J., Rudge J., et al., Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1 and VEGF, J. Clin. Invest., 2002, 109, 805-815.
42. Davoodi-Semiromi A., Yang J. J., She J. X., IL-12p40 is associated with type 1 diabetes in Caucasian-American families, Diabetes, 2002, 51, 2334-2336.